Ongoing clinical trials of FGFR-targeted therapy in UC
| Drugs | Targets | Combination | Conditions | Phase | NCT |
|---|---|---|---|---|---|
| Erdafitinib | FGFR2/3 | Null | Rec UC | FGFR3 gene mutation | II | NCT04917809 |
| Erdafitinib | FGFR2/3 | Null | UC | I | NCT05316155 |
| Erdafitinib | FGFR2/3 | Null | UC | I | NCT05567185 |
| Erdafitinib | FGFR2/3 | Gemcitabine + mitomycin C | UC | II | NCT04172675 |
| Erdafitinib | FGFR2/3 | Atezolizumab | UC | MIBC | II | NCT05564416 |
| Erdafitinib | FGFR2/3 | Enfortumab vedotin | Adv UC | I | NCT04963153 |
| Rogaratinib | FGFR1–3 | Null | UC | II | NCT04040725 |
| Rogaratinib | FGFR 1-3 | Atezolizumab | UC | I | NCT03473756 |
| Pemigatinib | FGFR1–3 | Null | Rec UC | NMIBC | II | NCT03914794 |
| Infigratinib | FGFR1–3 | Null | Solid Tumor | II | NCT05019794 |
| Infigratinib | FGFR1–3 | Null | Adv/Met malignant solid neoplasm | II | NCT04233567 |
| Infigratinib | FGFR1–3 | Null | Adv solid tumor | I/II | NCT05222165 |
| Infigratinib | FGFR1–3 | Null | UC | NMIBC | Not applicable | NCT02657486 |
| Futibatinib | FGFR1–4 | Null | UC | I/II | NCT02052778 |
| ICP-192 | FGFR 1–4 | Null | UC | II | NCT04492293 |
| ICP-192 | FGFR 1–4 | Null | UC | I/II | NCT04565275 |
| TYRA-300 | FGFR3 | Null | UC | I | NCT05544552 |
Null in Combination indicates that the trial is monotherapy. FGFR: fibroblast growth factor receptor; UC: urothelial carcinoma; MIBC: muscle-invasive bladder cancer; NMIBC: non-MIBC; Adv: advanced; Met: metastatic; Rec: recurrent; NCT: national clinical trial; ICP-192: gunagratinib; |: and